Cancer vaccines market will soar to $7.5 billion by 2022

Global revenues for the cancer vaccines market are forecast to grow at a compound annual growth rate of 16.93%, from $2.5 billion in 2015 to $7.5 billion in 2022.

Cancer vaccines are being developed as a method of preventing certain types of cancer, and as therapeutic treatments to treat existing cancers across a range of indications in oncology.

The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies, which have a lower toxicity associated with their use than traditional chemotherapies, investigation of a variety of anti-cancer immunotherapies, which have a lower toxicity associated with their use than traditional chemotherapies.

Therapeutic vaccine administration will increase the overall survival of poor-performance-status patients, and enable more rounds of treatment to be given – factors that will contribute to growing global revenues for this class of therapy. However, cancer vaccines are not perceived as having strong commercial potential, as immune checkpoint inhibitors are expected to dominate the treatment landscape for leukemia and lymphoma during the forecast period.

GBI Research’s latest report  Global Cancer Vaccines Market to 2022 – Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19  assesses the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis and visualize the composition of the cancer vaccines market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.

Request more information by using the form below:

Let’s get started...

Broker Rating Markets Available Fees Open an Account
Kawase Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 3.60 /5
(15 votes cast)
Loading...
Shares, Indices, Forex and Oil Spread From 0.1 and 0.2% Commission Visit Website
Plus500 Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 4.48 /5
(452 votes cast)
Loading...
Stocks, Commodities, Indices and Forex. Zero commissions. No monthly fees. $10 USD fee for unused account for a period of three months. Visit Website
MaxFx Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 4.70 /5
(89 votes cast)
Loading...
Indices, Forex, Metals, Shares From 0.1 Raw Interbank Spread Visit Website

Related Articles

29.06.2015.

Greece to Dominate Sentiment


03.08.2012.

FX Trade


Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.